REFERENCES
- Substance Abuse and Mental Health Services Administration . 2009 . Results from the 2008 National Survey on Drug Use and Health: National Findings , Washington, DC : Office of Applied Studies . NSDUH Series H-36, HHS Publication No. SMA 09-4434
- 2000 . Drug Addiction Treatment Act of 2000 and Pub . L. No. 106-310
- Ling , W and Wesson , D R . 2003 . Clinical efficacy of buprenorphine: comparisons to methadone and placebo . Drug Alcohol Depend , 70 ( 2s ) : s49 – s57 .
- Bell , J , Shanahan , M Mutch , C . 2007 . A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence . Addiction , 102 : 1899 – 1907 .
- Cicero , T and Inciardi , J A . 2005 . Potential for abuse of buprenorhpine on office-based treatment of opioid dependence . N Engl J Med , 353 : 1863 – 1864 .
- Gunderson , E , Fiellin , D A , Levin , F R , Sullivan , L E and Kleber , H D . 2006 . Evaluation of a combined online and in person training in the use of buprenorphine . Subst Abus , 27 : 39 – 45 .
- Walley , A , Alperen , J K Cheng , D M . 2008 . Office-based management of opioid dependence with buprenorphine: clinical practices and barriers . J Gen Intern Med , 23 : 1393 – 1398 .
- Lee , J , Grossman , E , DiRocco , D and Gourevitch , M N . 2008 . Home buprenorphine/naloxone induction in primary care . J Gen Intern Med , 24 : 226 – 232 .
- Mintzer , I , Eisenberg , M , Terra , M , MacVane , C , Himmelstein , D U and Wollhandler , S . 2007 . Treating opioid addiction with buprenorphine/naloxone in community-based primary care settings . Ann Fam Med , 5 : 146 – 150 .
- Sohler , N , Li , X Kunins , H V . 2010 . Home- versus office-based buprenorphine inductions for opioid-dependent patients . J Subst Abuse Treat , 38 : 153 – 159 .
- American Psychiatric Association . 1994 . Diagnostic and Statistical Manual of Mental Disorders , 4th ed , Washington, DC : American Psychiatric Association .
- Fudula , P , Bridge , T P Herbert , S . 2003 . Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone . N Engl J Med , 349 : 949 – 958 .